增持后，JPMorgan Chase & Co.最新持好仓数目为8684.107万股，持好仓比例由4.98%上升至5.06%。 | 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信建生物製藥 | | 日期(日 / 月 / 年): | 18/10/2025 - 18/11/2025 | 格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，信达生物(01801.HK)获JPMorgan Chase & Co.以每股均价84.7327港元增持好仓 143.88万股，涉资约1.22亿港元。 | Frida Barra | 大 股東/董事/最高行政人員名 作出披露的 買 入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法國 | | --- | --- | --- | --- | --- | --- | | | 版 分享 三 | | | 和人员上面落語 | 有投票樓股期(日/月/ 份權益 | | | | | | | 份自分比 年) | | CS20251114E00461 | JPMorgan Chase & ...

Core Insights - In 2024, China approved 48 innovative drugs for market entry, ranking second globally, just behind the United States with 50 approvals. In the first half of this year, the National Medical Products Administration approved 43 innovative drugs, marking a 59% year-on-year increase [1] Policy Guidance - Beijing has implemented a series of pioneering reforms in the pharmaceutical and health sector, including the establishment of green channels for rare disease drug approvals and optimizing clinical trial reviews. These measures aim to create a favorable environment for high-quality industry development [2] - The Beijing Municipal Science and Technology Commission has introduced 32 new measures to support the high-quality development of innovative pharmaceuticals and medical devices [2] - Chengdu has also rolled out specific policies to support the biopharmaceutical industry, focusing on drug and device R&D innovation and enhancing clinical research quality [2] Innovation Ecosystem - Chengdu's Tianfu International Biotech City is a key hub for the biopharmaceutical industry, housing 108 clinical research drugs, including 63 in clinical stages. The "Wutong Plan" launched by Chengdu High-tech Zone offers a comprehensive service list for the pharmaceutical health industry [3] - Jiangsu province has established a robust innovation ecosystem, exemplified by the production of the world's first dual-target weight-loss drug, which was approved in just 16 months [4] Comprehensive Innovation Efforts - Jiangsu has concentrated resources in policy, funding, and talent to strengthen its innovative platforms and tackle key technological challenges in the biopharmaceutical sector [5][6] - The National Biopharmaceutical Technology Innovation Center is focusing on critical technology R&D and public platform construction, with 66 projects already initiated [6] Capital Support - The capital market is increasingly supporting innovative drug development, with Beijing's Changping District establishing a multi-faceted investment framework, including a 200 billion yuan pharmaceutical investment fund [7] - The Zhongguancun Life Science Park in Changping has become a hub for cell and gene therapy, with over 20 companies advancing their products into clinical research [7] - Jiangsu's Shengsheng Biopharmaceutical Co. has committed to significant R&D investments, increasing its budget from 20 billion yuan in the first five years to nearly 80 billion yuan in the subsequent five years [7] Industry Layout - Under the dual support of policies and funding, various regions are accelerating their focus on cutting-edge fields, enhancing both the innovation and industrial chains [8] - The Suzhou Biopharmaceutical Industrial Park has gathered over 620 innovative pharmaceutical companies and more than 35,000 R&D talents, establishing a strong foundation for drug development and high-end medical devices [8]

智通财经APP获悉，香港联交所最新资料显示，11月11日，小摩增持信达生物(01801)143.8757万股，每 股作价84.7327港元，总金额约为1.22亿港元。增持后最新持股数目约为8684.11万股，最新持股比例为 5.06%。 ...

Group 1 - JPMorgan increased its stake in Innovent Biologics (01801) by acquiring 1,438,757 shares at a price of HKD 84.7327 per share, totaling approximately HKD 122 million [1] - Following the acquisition, JPMorgan's total shareholding in Innovent Biologics is approximately 86,841,100 shares, representing a stake of 5.06% [1]

Group 1 - The core viewpoint indicates a decline in innovative drug concept stocks, with notable drops in companies such as Kanglong Chemical, Kelun Pharmaceutical, and Xinlitai, among others [1] - The innovative drug-related ETFs have also experienced a decline, with an overall drop exceeding 2% [1] - Despite the downturn, there have been positive developments in China's biotechnology sector, including 35 research presentations at the ESMO 2025 conference and significant collaborations like the $11.4 billion partnership between Innovent Biologics and Takeda, highlighting global recognition of Chinese innovative drug value [2]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.12% with a trading volume of 2.214 billion yuan on November 14, 2024 [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of November 13, 2024, the fund's latest share count was 9.665 billion shares, with a total size of 8.579 billion yuan, reflecting a year-to-date increase of 2344.51% in shares and 2170.81% in size [1] Fund Performance - The current fund manager, Ma Jun, has achieved a return of 69.74% since taking over on January 3, 2024 [2] - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant weightings in the portfolio [2] Trading Activity - Over the past 20 trading days, the ETF has accumulated a trading volume of 28.057 billion yuan, averaging 1.403 billion yuan per day [1] - Year-to-date, the ETF has recorded a total trading volume of 251.214 billion yuan, with an average daily trading volume of 1.196 billion yuan [1]

Core Viewpoint - China Galaxy Securities reports that Innovent Biologics (01801) has become a leading biopharma company in China, excelling in innovative drug R&D, production, and commercialization, particularly in the oncology sector, which is expected to drive growth [1] Group 1: Financial Projections - The company is projected to achieve revenues of 11.891 billion, 14.836 billion, and 20.029 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits of 0.824 billion, 1.378 billion, and 2.059 billion yuan for the same years [1] Group 2: Strategic Partnership with Takeda - On October 22, 2025, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical to accelerate the global rollout of next-generation IO and ADC therapies, including IBI363, IBI343, and IBI3001, with an upfront payment of 1.2 billion USD and potential milestone payments totaling up to 11.4 billion USD [1] Group 3: Development of IBI363 - Innovent will co-develop IBI363 with Takeda, sharing development costs at a 40/60 ratio, and profits in the U.S. market will also be split 40/60, with Takeda leading the development [2] - IBI363 has shown promising data at the 2025 ASCO meeting, with a cORR of 36.7%, mPFS of 9.3 months, and a 12-month OS rate of 70.9%, with a global Phase III clinical plan set to launch soon [2] Group 4: Rights Granted for IBI343 and IBI3001 - Innovent has granted Takeda exclusive rights to IBI343 outside of Greater China, with potential milestone payments and high-tier sales sharing [3] - Takeda will focus on the global development of IBI343, particularly in first-line gastric and pancreatic cancer, while IBI3001's rights outside Greater China are also available for Takeda to exercise in the future [3]

Core Viewpoint - Xinda Biopharma has established itself as a leading player in China's biopharmaceutical sector, particularly in the oncology field, and is expected to continue its growth trajectory with new strategic partnerships and product developments [1] Group 1: Strategic Partnership - On October 22, 2025, Xinda Biopharma entered into a global strategic collaboration with Takeda Pharmaceutical to accelerate the global rollout of next-generation IO and ADC therapies, involving three products: IBI363, IBI343, and IBI3001 [1] - The collaboration includes an upfront payment of $1.2 billion (including a $100 million premium for strategic equity investment) and potential milestone payments, with a total deal value reaching up to $11.4 billion [1] Group 2: Product Development and Commercialization - Xinda will co-develop IBI363 with Takeda, sharing development costs at a 40/60 ratio and splitting profits from commercialization in the U.S. market similarly [2] - IBI363 has shown promising data at the 2025 ASCO conference, with a cORR of 36.7%, mPFS of 9.3 months, and a 12-month OS rate of 70.9% for immune-resistant NSCLC, with a global Phase III clinical plan set to launch soon [2] Group 3: ADC Product Rights - Xinda granted Takeda exclusive rights to IBI343 outside of Greater China, which includes potential milestone payments and high-tier percentage sales sharing [3] - IBI343 is currently undergoing Phase III clinical trials for gastric cancer in China and Japan, and has completed global Phase I/II trials for PDAC [3] - Additionally, Xinda has granted Takeda an option for early pipeline IBI3001 outside of Greater China, which could yield option fees, milestone payments, and high-tier sales sharing if exercised [3]

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug stocks in the market, with notable increases in share prices for companies such as Gilead Sciences-B (up 8.82%) and Kintor Pharmaceutical (up 4.60%) [1] - The report from CICC emphasizes the importance of innovative drugs and medical devices in China's "14th Five-Year Plan," indicating a shift from "follow-up innovation" to "quality transformation" in domestic innovative drugs [1] - The collaboration between Hansoh Pharmaceutical and Roche for the global exclusive license of the antibody-drug conjugate HS-20110 is seen as a significant advancement, with expectations for smooth development due to Roche's expertise [2] Group 2 - The partnership between Innovent Biologics and Takeda Pharmaceutical aims to advance the development of next-generation tumor immunotherapy and antibody-drug conjugates, leveraging Takeda's strong sales network in Japan and the West [2] - Valiant Pharmaceuticals' agreement with the U.S. company Dianthus for the development and commercialization of its autoimmune drug LBL-047 outside Greater China is viewed as beneficial for product development [2] - The overall sentiment in the pharmaceutical industry is optimistic regarding the international expansion of innovative drugs, with multiple companies securing significant partnerships to enhance their research and commercialization efforts [2]

Group 1 - The Hang Seng Index rose by 0.56% to close at 27,073.03 points on November 13, with a total net sell of 3.52 billion HKD through the southbound trading channel [1] - The total trading amount for the southbound trading on November 13 was 124.97 billion HKD, with a net sell of 3.52 billion HKD [1] - The Shanghai Stock Exchange's southbound trading had a total trading amount of 75.99 billion HKD and a net sell of 2.13 billion HKD, while the Shenzhen Stock Exchange had a total trading amount of 48.98 billion HKD and a net sell of 1.39 billion HKD [1] Group 2 - In the top ten active stocks for the Shanghai Stock Exchange's southbound trading, Alibaba-W had the highest trading amount of 9.91 billion HKD, followed by the Tracker Fund of Hong Kong and SMIC with trading amounts of 4.27 billion HKD and 3.44 billion HKD respectively [2] - Alibaba-W had a net buy amount of 1.70 billion HKD, with its stock price increasing by 3.32% [2] - The Tracker Fund of Hong Kong had the highest net sell amount of 4.26 billion HKD, while its stock price increased by 0.52% [2] Group 3 - In the Shenzhen Stock Exchange's southbound trading, Alibaba-W also led with a trading amount of 5.99 billion HKD, followed by SMIC and Tencent Holdings with trading amounts of 2.61 billion HKD and 2.27 billion HKD respectively [2] - The highest net buy amount was for Huahong Semiconductor at 196 million HKD, with its stock price rising by 5.64% [2] - The highest net sell amount was again for the Tracker Fund of Hong Kong at 196 million HKD, with its stock price increasing by 0.52% [2]